In a new report on South Korea's pharmaceuticals and health care industry, Business Monitor International describes the country as a transitional pharmaceutical market. Characteristic of an emerging market, combined sales of prescription drugs and over-the-counter (OTC) medicines are forecast to post high single-digit compound annual growth rates (CAGRs) over the next five years. However, the operating environment is similar to that seen in traditional markets.
South Korea's Pharmaceutical Business Environment Rating (BER) has increased from 66.9 out of 100 in third-quarter 2010 to 67.0 in the fourth quarter, due to a slight improvement in BMI’s evaluation of the Country Risks. Enjoying this article?
